Prevalence of drug-drug interactions in cancer patients treated with anti-cancer drugs.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON22087

Enrollment

500

Registered

2012-12-19

Start date

2013-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, chemotherapy, drug-drug interactions, oncology, pharmacology, risk factors.

Interventions

Medication review in oncology.

Eligibility

Inclusion criteria

Inclusion criteria: All ambulatory patients with the diagnosis of a solid tumour or a haematological malignancy, who are receiving one or more (oral) anti-cancer therapies, are included in the study.

Exclusion criteria

Exclusion criteria: 1. The use of experimental trial agents; 2. Age <18 years; 3. The use of anti-cancer drugs for non-malignant diseases.

Design outcomes

Primary

Measure	Time frame
Prevalence of drug-drug interactions (DDI's) and the clinical consequence of these DDI's.	—

Secondary

Measure	Time frame
The secondary objective is to obtain more insight into possible determinants for the occurrence of these DDIs.	—

Contacts

Public ContactRoelof Leeuwen, van

Erasmus University Medical Center, Department of Pharmacy ´s-Gravendijkwal 230

r.w.f.vanleeuwen@erasmusmc.nl+31 (0)10 7033202

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)